New drug combo aims to shrink lung tumors enough for surgery
NCT ID NCT07408635
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests whether a new drug called IBI363, combined with standard chemotherapy, can shrink stage III non-small cell lung cancer that was initially too advanced to remove with surgery. The goal is to make the tumors operable, then remove them. About 43 adults with unresectable stage III NSCLC will receive the combination before a surgical evaluation. The study measures how many patients achieve complete tumor removal and how well they respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IBI363 (a drug that targets PD-1 and IL-2) combined with platinum-based chemotherapy
- What this could lead to
- If successful, this approach could turn some inoperable lung cancers into operable ones, potentially improving survival and cure rates.
- What could go wrong
- This is a small, early-phase trial with only 43 participants and no comparison group. The combination may cause significant side effects, and not all patients will become eligible for surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Pulmonary Hospital
RECRUITINGShanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New immunotherapy combo aims to improve lung cancer outcomes
- New combo aims to turn untreatable lung tumors into surgical candidates
- New drug combo may make inoperable lung cancer removable
- New chemo formula aims to keep lung cancer away after surgery
- New blood test could spot lung cancer mutations more accurately